{
  "docId": "019de514-6ff5-7310-813b-bef8d5f9ec91",
  "docSlug": "dbbeae38634aeeee4a36f290777f18f9",
  "documentTitle": "Vivani Medical | Mergers and Acquisitions Presentation Deck | 27 slides",
  "authorId": "vivani-medical",
  "authorName": "Vivani Medical",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 27,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide outlines a randomized clinical trial structure with three arms of 20 patients each.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-6ff5-7310-813b-bef8d5f9ec91/19",
  "deckHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91",
  "deckJsonHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91.json",
  "deckAnchorHref": "/decks/019de514-6ff5-7310-813b-bef8d5f9ec91#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.42,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Randomization flow into three arms: NPM-119 Low Dose (N=20), NPM-119 High Dose (N=20), Bydureon BCise 2mg/week (N=20)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03bc41f5-598f-4444-baff-b9e086484fdb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.07,
        "y": 0.35
      },
      "kind": "list",
      "text": "Key Inclusion/Exclusion Criteria: T2DM and HbA1c ≥6.5% and <10.0%; On non-exenatide GLP-1 therapy; May be taking GLP-1 in combination with up to 2 of: metformin, TZD, SGLT-2 inhibitor, or DPP-4 inhibitor; Excluded: SU, insulin",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "704a284e-269e-4d04-a13d-09be6be7b3a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.65,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Primary Objectives: Safety/tolerability assessment and full PK characterization\nSecondary Objective: Evaluate change from baseline in glycemic control (HbA1c)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84d3dd3a-965b-4f07-9d6d-9d7757be22cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "T2DM: Type 2 Diabetes Mellitus; TZD: Thiazolidinedione; SGLT-2: Sodium-glucose cotransporter-2; DPP-4: Dipeptidyl peptidase 4; SU: Sulfonylurea",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3cf1b7e-5213-4159-8535-8fe938861b8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "Proposed First in Human Trial: LIBERATE-1",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fd3bd49-6bdd-4f0f-a2b3-fed787b60fe1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "71701d25-bd73-4ed7-9154-f82d7a7e461e",
      "evidence": "Key Inclusion/Exclusion Criteria: T2DM and HbA1c ≥6.5% and <10.0%",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}